Our News on Newswise

Allison Institute announces formation of scientific advisory board

The James P. Allison Institute at MD Anderson today announced the establishment of its scientific advisory board to provide strategic guidance and evaluation of its research portfolio and programs.
15-Aug-2022 10:00 AM EDT Add to Favorites

Newswise: 62f668a229403_viveksubbiah.jpg

Pralsetinib achieves tissue-agnostic benefits for patients with RET gene fusions

The targeted therapy pralsetinib was well-tolerated and demonstrated high response rates in patients with RET gene fusions regardless of tumor type, according to results from the Phase I/II ARROW trial.
12-Aug-2022 12:00 PM EDT Add to Favorites

MD Anderson Research Highlights for August 10, 2022

The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Current advances include using a CRISPR screen to identify targets...
10-Aug-2022 2:00 PM EDT Add to Favorites

MD Anderson and Empyrean announce agreement to develop novel radiation therapy technologies

MD Anderson and Empyrean announced an exclusive license and joint development agreement to advance new technologies and products in radiation oncology.
10-Aug-2022 9:00 AM EDT Add to Favorites

MD Anderson and TransCode Therapeutics announce strategic alliance to advance RNA therapies for oncology

MD Anderson and TransCode announced a strategic alliance to advance TransCode's pipeline of RNA-targeted therapeutic and diagnostic candidates for oncology.
2-Aug-2022 7:00 AM EDT Add to Favorites

MD Anderson to host virtual Cancer Neuroscience Symposium

MD Anderson will host the virtual Cancer Neuroscience Symposium Sept. 22-23, 2022, in collaboration with the journal Advanced Biology. The symposium is free to attend and gathers leading experts in the field to discuss a variety of topics on the...
1-Aug-2022 9:40 AM EDT Add to Favorites

MD Anderson Research Highlights for July 27, 2022

Clinical advances include treating hematologic cancers with effective targeted therapies, circulating tumor DNA as a biomarker for recurrence with colorectal liver metastases, and using magnetic resonance imaging (MRI) to guide surgical decisions...
27-Jul-2022 12:00 PM EDT Add to Favorites

MD Anderson named #1 in the nation for cancer care

The University of Texas MD Anderson Cancer Center today was named number one in the nation for cancer care in U.S. News & World Report’s 2022-23 “Best Hospitals” rankings.
25-Jul-2022 11:05 PM EDT Add to Favorites


See All News

Our Experts on Newswise

Newswise: BenjaminSmith.jpg

Mastectomy Plus Reconstruction Has Highest Rate of Complication, Complication-Related Costs of Guideline-Concordant Therapies for Early Breast Cancer

In a review of guideline-concordant treatment modalities for women with early stage breast cancer, mastectomy and reconstruction had the highest rate of complications and complication-related costs, regardless of age.
27-Sep-2016 3:05 PM EDT

Newswise: Liang_H_Bronto.jpg

Can Gender Play a Role in Determining Cancer Treatment Choices?

It is well known that men and women differ in terms of cancer susceptibility, survival and mortality, but exactly why this occurs at a molecular level has been poorly understood.
9-May-2016 12:00 PM EDT

Newswise: ZhiminLu.jpg

MD Anderson Study Reveals New Insight Into Tumor Progression

Scientists know that activation of growth factor receptors like epidermal growth factor receptors (EGFR) promote tumor progression in many types of cancer.
17-Aug-2015 11:00 AM EDT

Newswise: Lee_M.jpg

Poor Survival Among Colorectal Cancer Patients Tied to Biomarker CSN6

A protein called CSN6 has been found to be correlated with poor survival among patients with colorectal cancer, according to a study at The University of Texas MD Anderson Cancer Center.
10-Aug-2015 12:00 PM EDT

Newswise: 204929_Chhatwal_Jjpg.jpg

MD Anderson Study Predicts New Hepatitis C Drugs Will Place a Dramatic Financial Strain on the Health Care System

The cost of treating people infected with the hepatitis C virus (HCV) with newly approved therapies will likely place a tremendous economic burden on the country’s health care system. The prediction comes from a cost-effectiveness analysis led by...
16-Mar-2015 6:00 PM EDT

MD Anderson Joins CATCH Global Foundation to Boost Child Health, Prevent Cancer in Later Years

Cancer prevention experts at The University of Texas MD Anderson Cancer Center have allied with the CATCH Global Foundation, whose comprehensive child health program reaches children and their families in more than 10,000 educational settings...
18-Feb-2015 10:00 AM EST

MD Anderson Energy Balance Expert Available for Obesity, Cancer Stories

30-Oct-2013 8:10 PM EDT

MD Anderson Obesity and Cancer Expert Researches Food Addiction

30-Oct-2013 8:00 PM EDT

See All Experts

Our YouTube Videos

About

The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. The institution’s sole mission is to end cancer for patients and their families around the world. MD Anderson is one of only 53 comprehensive cancer centers designated by the National Cancer Institute (NCI). MD Anderson is No.1 for cancer in U.S. News & World Report’s “Best Hospitals” rankings, and has been named one of the nation’s top two hospitals for cancer since the rankings started in 1990. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).

Contacts

Clayton Boldt
Program Director, Public Relations

crboldt@mdanderson.org

713-792-9518

Katrina Burton
Program Manager, Public Relations

kburton@mdanderson.org

713-792-8034

Lany Kimmons
Program Manager, Public Relations

rlkimmons@mdanderson.org

713-563-5801

Julie Nagy
Program Manager, Public Relations

jenagy@mdanderson.org

713-563-3437

Meagan Raeke
Program Manager, Public Relations

meraeke@mdanderson.org

713-563-9340

Allison Schaffer
Program Manager, Public Relations

ASchaffer@mdanderson.org

713-745-1357

Twitter

close
0.47649